Drugs / Dulaglutide
Dulaglutide
also known as
LY2189265 · dulaglutide injection · TRULICITY · Dulaglutida · dulaglutide (Trulicity) · Dulaglutide component of trulicity
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | TRULICITY | — | 2017-01-27 – 2022-11-17 | fda.gov ↗ |
| Approved | EU (EMA) | Trulicity | — | 2014-11-21 | europa.eu ↗ |
| Approved | US (FDA) | TRULICITY | — | 2014-09-18 | fda.gov ↗ |
Trials 73 · started per year
today
US approved 2014
EU approved 2014
3
1
8
9
8
1
1
1
4
3
2
5
5
6
3
4
3
4
2
200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT07313813 | Dec 2025 → Aug 2026 overdue | type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03363906 | Dec 2017 → Jun 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01667900 | Aug 2012 → Jun 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01524770 | Mar → Jun 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01458210 | Oct 2011 → Feb 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01436201 | Sep → Nov 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01432938 | Sep → Dec 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01408888 | Aug 2011 → Apr 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01324388 | Mar → Aug 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01301092 | Feb → Aug 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01300260 | Feb → Aug 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01250834 | Dec 2010 → Mar 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01253304 | Nov 2010 → Nov 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01215968 | Sep 2010 → Jul 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04466904 | Sep 2020 → May 2021 | type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT07370922 | Nov 2024 → Nov 2025 | beta-thalassemia major | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT06148649 | Dec 2023 → Feb 2025 | type 2 diabetes mellitus | Dongguan HEC Biopharmaceutical R&D Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05254418 | Mar 2022 → May 2024 | chronic kidney disease | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04731272 | Jul 2021 → Jun 2027 expected | cystic fibrosis, diabetes mellitus, exocrine pancreatic insufficiency, glucose intolerance | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 2 | NCT04687514 | May 2021 → Sep 2022 | physiological sexual disorder | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 2 | NCT03668470 | Jan 2019 → Feb 2021 | type 1 diabetes mellitus | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 2 | NCT02973100 | Dec 2016 → Jul 2017 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT02770885 | Mar 2016 → May 2019 | primary polydipsia | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 2 | NCT01149421 | Jun 2010 → Sep 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01001104 | Oct 2009 → Dec 2010 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00791479 | Dec 2008 → Jan 2010 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00630825 | Apr 2008 → Jan 2009 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07282041 | Dec 2025 → Dec 2030 expected | intracranial arteriosclerosis, ischemic stroke | National University of Singapore | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00734474 | Aug 2008 → Jun 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 323 trials | ||||||
| Phase 3 | NCT06739122 | Jan 2025 → Dec 2027 expected | type 2 diabetes mellitus | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06235086 | Apr 2024 → Feb 2026 | type 2 diabetes mellitus | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05606913 | Jan 2023 → Jan 2024 | type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04809220 | Apr 2021 → Oct 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04591626 | Dec 2020 → Apr 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT04255433 | May 2020 → Jun 2025 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03495102 | Apr 2018 → May 2019 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02963766 | Dec 2016 → Jun 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02597049 | Nov 2015 → Feb 2017 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02152371 | May 2014 → Oct 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01769378 | Jan 2013 → Dec 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01648582 | Jul 2012 → Aug 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01644500 | Jul 2012 → Aug 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01621178 | Jul 2012 → Jun 2016 | chronic kidney disease, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01624259 | Jun 2012 → Nov 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01584232 | Apr 2012 → Jul 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01558271 | Mar 2012 → Oct 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01468181 | Nov 2011 → Dec 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01394952 | Jul 2011 → Aug 2018 | cardiovascular disorder, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01191268 | Nov 2010 → Feb 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01126580 | May 2010 → Nov 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01075282 | Feb 2010 → May 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01064687 | Feb 2010 → Nov 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 417 trials | ||||||
| Phase 4 | NCT07027969 | Nov 2026 → Dec 2029 expected | atrial fibrillation, obesity disorder | Ali Aminian | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07537088 | May 2026 → Apr 2027 expected | chronic kidney disease, type 2 diabetes mellitus | First Affiliated Hospital of Wannan Medical College | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06851962 | May 2025 → Jun 2026 overdue | type 2 diabetes mellitus | Fundación para la Investigación del Hospital Clínico de Valencia | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06324461 | Mar 2024 → Dec 2028 expected | — | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 4 | NCT05140694 | Dec 2023 → Jun 2024 | metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05659537 | Dec 2022 → Jan 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT05218915 | Jan 2022 → Oct 2024 | diabetes mellitus, diabetic kidney disease | Elaine Chow | Completed | No outcome recorded |
| Phase 4 | NCT04862234 | Aug 2021 → Jun 2023 | hyperglycemia | Emory University | Terminated | No outcome recorded |
| Phase 4 | NCT04876027 | May 2021 → Apr 2022 | polycystic ovary syndrome | Shanghai 10th People's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04387201 | May 2020 → Oct 2023 | glucose intolerance, obesity disorder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT04135287 | Mar 2020 → Mar 2023 | type 2 diabetes mellitus | Dasman Diabetes Institute | Unknown | No outcome recorded |
| Phase 4 | NCT04189848 | Dec 2019 → Jan 2020 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT03648554 | Sep 2019 → Sep 2023 | metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | Central Hospital, Nancy, France | Unknown | No outcome recorded |
| Phase 4 | NCT03743025 | Mar 2019 → May 2023 | hyperglycemia | Emory University | Terminated | No outcome recorded |
| Phase 4 | NCT03315780 | Oct 2017 → Feb 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT03824002 | Apr → Oct 2017 | type 2 diabetes mellitus | University of Palermo | Completed | No outcome recorded |
| Phase 4 | NCT02750410 | Aug 2016 → Jun 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT06331286 | Sep 2023 → Dec 2024 | bipolar disorder, obesity disorder | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| — | NCT06182891 | Oct 2021 → Jun 2023 | diabetic kidney disease | The Affiliated Hospital of Xuzhou Medical University | Completed | No outcome recorded |
| — | NCT03590626 | Jan 2019 → Jan 2020 | fatty liver disease, type 2 diabetes mellitus | Medanta, The Medicity, India | Completed | No outcome recorded |
| — | NCT03498001 | Apr 2018 → Jun 2023 | type 2 diabetes mellitus | Centre Hospitalier Universitaire Dijon | Completed | No outcome recorded |
Also used as a comparator or background therapy in 40 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT05516966 Comparator | Oct 2022 → May 2023 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05407961 Background | Jun 2022 → Jan 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05377333 Background | Jun 2022 → Nov 2023 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05459285 Comparator | May → Jul 2022 | type 2 diabetes mellitus | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04641312 Background | Nov 2020 → Dec 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04515576 Comparator | Aug 2020 → Mar 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04143802 Comparator | Dec 2019 → Dec 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02759107 Comparator | May 2016 → Jun 2017 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07319286 Comparator | Aug 2025 → Dec 2026 expected | menstrual disorder, type 1 diabetes mellitus | Ain Shams University | Enrolling by invitation | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07677891 Comparator | Oct 2026 → May 2027 expected | type 2 diabetes mellitus | ProGen. Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07109700 Comparator | Apr 2025 → Jan 2026 overdue | type 2 diabetes mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06901648 Comparator | Feb 2024 → Mar 2025 | type 2 diabetes mellitus | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05478707 Comparator | Oct 2023 → Jun 2028 | type 1 diabetes mellitus | University of Virginia | Suspended | No outcome recorded |
| Phase 2 | NCT05348122 Comparator | Jun 2022 → Nov 2023 | type 2 diabetes mellitus | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05048719 Comparator | Sep 2021 → Sep 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT04867785 Comparator | May 2021 → Jul 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT03962010 Comparator | Jun 2019 → Jun 2022 | type 2 diabetes mellitus | Genexine, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT03204396 Comparator | Jun 2017 → Jul 2022 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 2 | NCT03131687 Comparator | May 2017 → Aug 2018 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT03141632 Comparator | Oct 2016 → May 2017 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT07668336 Comparator | Sep 2026 → Mar 2030 expected | type 2 diabetes mellitus | Eli Lilly and Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07156539 Comparator | Sep 2025 → Mar 2027 expected | type 2 diabetes mellitus | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06257966 Comparator | Jul 2024 → Oct 2026 expected | type 2 diabetes mellitus | Beijing Dongfang Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05680129 Comparator | Jan 2023 → Jul 2024 | type 2 diabetes mellitus | Hangzhou Sciwind Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03861052 Comparator | May 2019 → Mar 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03684642 Comparator | Sep 2018 → Oct 2020 | type 2 diabetes mellitus | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT03015220 Comparator | Jan 2017 → Jul 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02787551 Comparator | Jul 2016 → May 2018 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02648204 Comparator | Jan 2016 → Apr 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT07325435 Comparator | Dec 2024 → Dec 2027 expected | type 2 diabetes mellitus | MaryAnn Banerji | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06449235 Comparator | Sep 2024 → Apr 2025 overdue | type 2 diabetes mellitus | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06533527 Comparator | Jul 2024 → May 2025 | gastroparesis, obesity disorder, type 2 diabetes mellitus | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT05564039 Comparator | Nov 2022 → Jul 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT05390892 Comparator | Sep 2022 → Mar 2029 expected | atherosclerotic cardiovascular disease, type 2 diabetes mellitus | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05005741 Comparator | May 2021 → Dec 2023 | obesity disorder, type 2 diabetes mellitus | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT04893148 Comparator | May 2020 → Dec 2021 | hyperglycemia, type 2 diabetes mellitus | Chungbuk National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03444142 Comparator | Nov 2017 → Nov 2021 | type 2 diabetes mellitus | University of Guadalajara | Unknown | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT04829903 Comparator | Jan 2020 → Mar 2021 | obesity disorder, type 2 diabetes mellitus | Corporacion Parc Tauli | Completed | No outcome recorded |
| — | NCT06611904 Comparator | Feb 2018 → Feb 2022 overdue | arteriosclerosis disorder, proteinuria | Attikon Hospital | Active not recruiting | No outcome recorded |
| — | NCT02846233 Comparator | Aug 2016 → Dec 2018 | type 2 diabetes mellitus | University of California, San Francisco | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-09-20 | Novo Nordisk A/S | Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes novonordisk.com ↗ |
| 2017-08-16 | Novo Nordisk A/S | Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7 novonordisk.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 117 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dulaglutide | “A Phase 2, 12-Week, Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate Efficacy and Safety of GX-G6 on Glycaemic Control Versus Placebo and Open-Label...” NCT03962010 ↗94“The potential effect of the GLP-1 RA dulaglutide on the pharmacokinetics (PK) of four orally administered drugs and on the pharmacodynamic (PD) effect of warfarin was investigated.” PMID 28357715 ↗ Nov 2017 “Chemical Name: GLP-1 Receptor Agonists (GLP1RA) (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: Glucagon-Like Peptide-1 Receptor Agonists” NCT06449235 ↗ “This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin).” NCT04189848 ↗ “The choice of AOMs considered may include metformin, topiramate, liraglutide, dulaglutide, semaglutide, tirzepatide, and empagliflozin.” NCT07027969 ↗ “LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks” NCT01126580 ↗ “Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg” NCT03498001 ↗ “Albiglutide (Tanzeum) or , Dulaglutide (Trulicity)” NCT02846233 ↗ “Dulaglutide, liraglutide, semaglutide” NCT05390892 ↗ “dulaglutide 1.5 mg per week” NCT04135287 ↗ “dulaglutide (Trulicity)” NCT07325435 ↗ “Dulaglutide” NCT04876027 ↗ |
| Known as | Dulaglutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108027 ↗ |
| Known as | dulaglutide (Trulicity) | “dulaglutide (Trulicity)” NCT07325435 ↗ |
| Known as | Dulaglutide component of trulicity | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108027 ↗ |
| Known as | dulaglutide injection | “Drug: dulaglutide injection” NCT06331286 ↗1“Drug: Dulaglutide Injection” NCT06182891 ↗ |
| Known as | LY2189265 | “A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus” NCT02597049 ↗ |
| Known as | TRULICITY | “Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.” NCT03141632 ↗1“dulaglutide (TRULICITY®) 1.5 mg” NCT03648554 ↗ |
| Action | Activate | “once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist” PMID 24762094 ↗ May 2014 |
| Modality | Peptide | “a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue” PMID 28573765 ↗ Jul 2017 |
| Route | Subcutaneous | “subcutaneous (SC) injection” NCT00630825 ↗ |
| Target | GLP1R | “injectable GLP-1RA dulaglutide 0.75 mg” PMID 33460016 ↗ Jan 2021 |